Pirouette Medical was founded by three rocket scientists who met in college—looking to improve the human condition by placing healthcare in the hands of the patient.
The trio enjoys working together on difficult problems, whether that is rocket technology or innovative medical solutions. Although it could have been Pirouette Aerospace, the trio chose to advocate on behalf of patients and tackle a specific need for healthcare innovation—launching Pirouette Medical.
So long as there are humans with the need to keep being—we will continue
without pause or rest, to place healthcare in the hands of the patient.
- Instructions for use are located on top for clear visibility before and during use.
- As patients would expect, the safety cap covers the area where the needle emerges.
- Upon removal of the safety cap, the injector is oriented correctly and helps reduce incidents of incorrect application.
- The oversized and ridged cap provides a natural gripping surface.
- The medical grade adhesive "bottom" indicates the correct surface to be applied to the skin/clothing and helps hold the device in place.
- Post-use indicators include bright red "Used" labeling, fully retracted needle, device lockout feature, and successful delivery.
Our Beachhead: The Future of Anaphylaxis Treatment
Pirouette Medical understands that to transform the patient experience, our products must first and foremost be affordable to all patients. Beyond affordability our entire product line will deliver on the key competitive market attributes of portability, usability and ultimately—patient peace of mind.
Over 50,000,000 Americans are believed to be affected by anaphylaxis, with triggers that include latex, peanuts, insect stings and drug interaction.
“Pirouette’s revolutionary device brings affordability, portability, and usability directly to the patients that need it, making the administration of an injection as easy as pushing a button. The platform technology is applicable to a wide variety of drugs with both emergency and non-emergency applications.”
Conor R. Cullinane, Ph.D., CEO